Search results for "Hazard"

showing 10 items of 1517 documents

Total polyphenol intake, polyphenol subtypes and incidence of cardiovascular disease: The SUN cohort study.

2018

Abstract Background and aims Polyphenol-rich diets have been associated with reduced risk of cardiovascular disease (CVD). However, few prospective epidemiological studies have examined the relationship between classes of ingested polyphenols and risk of CVD. Our aim was to evaluate the association between polyphenol intake and risk of major cardiovascular events in a prospective Spanish cohort. Methods and results We included 17,065 university graduates (60.7% women, mean age: 37.2 years, age range: 20–89) followed-up for a mean of 10.1 years. Polyphenol intake was assessed at baseline using a validated semi-quantitative 136-item food frequency questionnaire and matching food consumption d…

AdultMalemedicine.medical_specialtyTime FactorsUniversitiesEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030209 endocrinology & metabolism030204 cardiovascular system & hematologyDiet Surveys03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineEpidemiologymedicineHumansProspective StudiesProspective cohort studyStudentsAgedAged 80 and overNutrition and Dieteticsbusiness.industryProportional hazards modelIncidence (epidemiology)IncidenceHazard ratioConfoundingfood and beveragesPolyphenolsMiddle AgedProtective FactorsDietCardiovascular DiseasesSpainCohortFemaleCardiology and Cardiovascular MedicinebusinessCohort studyNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multi…

2008

Summary Background Carotid stenting is a potential alternative to carotid endarterectomy but whether this technique is as safe as surgery and whether the long-term protection against stroke is similar to that of surgery are unclear. We previously reported that in patients in the Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial, the rate of any stroke or death within 30 days after the procedure was higher with stenting than with endarterectomy. We now report the results up to 4 years. Methods In this follow-up study of a multicentre, randomised, open, assessor-blinded, non-inferiority trial, we compared outcome after stenting with outcome …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCarotid endarterectomyRisk AssessmentSeverity of Illness IndexFunctional LateralityDouble-Blind MethodRisk FactorsInternal medicineAngioplastyClinical endpointConfidence IntervalsMedicineHumansCarotid StenosisLife Tablescardiovascular diseasesLongitudinal StudiesStrokeEndarterectomyAgedProportional Hazards ModelsRetrospective StudiesEndarterectomy Carotidbusiness.industryHazard ratioAngioplastyMiddle Agedmedicine.diseaseSurgeryStrokeStenosisTreatment OutcomeCardiologyFemaleNeurology (clinical)Carotid stentingbusinessThe Lancet. Neurology
researchProduct

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph nod…

2009

OBJECTIVE To investigate the associations between different overall or topographically restricted lymph node (LN) variables and cancer-specific survival (CSS) after radical cystectomy (RC) and extended LN dissection (LND) with curative intent in patients with LN-positive bladder cancer. PATIENTS AND METHODS Between 2001 and 2006, 152 patients had RC with standardized extended LND for bladder cancer with curative intent. Patients with positive LNs were stratified according to the median of the LN variables (LNs removed, number of positive LNs, LN density). CSS was related to overall and topographically restricted LN variables, e.g. different levels of LND, and relationships were tested by un…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyCystectomymedicineCarcinomaHumansLymph nodeAgedAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryHazard ratioCancerMiddle AgedPrognosismedicine.diseaseConfidence intervalSurgeryTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic MetastasisLymph Node ExcisionFemaleLymphadenectomyEpidemiologic MethodsbusinessBJU International
researchProduct

Dietary habits are related to outcomes in patients with advanced heart failure awaiting heart transplantation.

2012

Abstract Background Empirical evidence supporting the benefits of dietary recommendations for patients with advanced heart failure is scarce. We prospectively evaluated the relation of dietary habits to pre-transplant clinical outcomes in the multisite observational Waiting for a New Heart Study. Methods and Results A total of 318 heart transplant candidates (82% male, age 53 ± 11 years) completed a Food Frequency Questionnaire (foods high in salt, saturated fats, poly-/monounsaturated fats [PUFA+MUFA], fruit/vegetables/legumes, and fluid intake) at time of waitlisting. Cox proportional hazard models controlling for heart failure severity (eg, Heart Failure Survival Score, creatinine) estim…

AdultMalemedicine.medical_specialtyWaiting ListsSaturated fatmedicine.medical_treatmentSeverity of Illness IndexInternal medicineSurveys and QuestionnairesSeverity of illnessmedicineHumansProspective StudiesSodium Chloride DietaryProspective cohort studyHeart transplantationHeart Failurebusiness.industryHazard ratioFeeding BehaviorMiddle Agedmedicine.diseaseDietary FatsConfidence intervalSurgeryTransplantationTreatment OutcomeHeart failureHeart TransplantationFemaleCardiology and Cardiovascular MedicinebusinessJournal of cardiac failure
researchProduct

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicen…

2019

Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. Methods PSC-IBD patients were identified from the Spanish ENEIDA registry of GETECCU. Additional data were collected using the AEG-REDCap electronic data capture tool. Results In total, 277 PSC-IBD patients were included, with an incidence rate of 61 PSC cases per 100 000 IBD patient-years, 69.7% …

AdultMalemedicine.medical_specialtyendocrine system diseasesColorectal cancerCholangitis SclerosingRisk AssessmentGastroenterologyInflammatory bowel diseasedigestive systemPrimary sclerosing cholangitisCholangiocarcinomaBile Ducts ExtrahepaticRisk FactorsInterquartile rangeinflammatory bowel diseaseInternal medicineHumansMedicineRetrospective Studiesbusiness.industryPrimary sclerosing cholangitisHazard ratiodigestive oral and skin physiologyGastroenterologyRetrospective cohort studyGeneral MedicineOdds ratioMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurvival AnalysisUlcerative colitisdigestive system diseasesPatient Care ManagementBile Ducts IntrahepaticSpainFemalePrimary sclerosing cholangitis inflammatory bowel disease malignancyColorectal Neoplasmsbusinessmalignancy
researchProduct

Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation base…

2008

Abstract Residual vein thrombosis (RVT) indicates a prothrombotic state and is useful for evaluating the optimal duration of oral anticoagulant treatment (OAT). Patients with a first episode of deep vein thrombosis, treated with OAT for 3 months, were managed according to RVT findings. Those with RVT were randomized to either stop or continue anticoagulants for 9 additional months, whereas in those without RVT, OAT was stopped. Outcomes were recurrent venous thromboembolism and/or major bleeding. Residual thrombosis was detected in 180 (69.8%) of 258 patients; recurrent events occurred in 27.2% of those who discontinued (25/92; 15.2% person-years) and 19.3% of those who continued OAT (17/88…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinImmunologyHemorrhageBiochemistryDrug Administration ScheduleSettore MED/15 - Malattie Del SangueDeep vein thrombosioral anticoagulantSecondary PreventionmedicineHumansAgedUltrasonographyVenous ThrombosisFirst episoderesidual vein thrombosisVascular diseasebusiness.industryAnticoagulantHazard ratioAnticoagulantsCell BiologyHematologyMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisConfidence intervalSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemalebusinessBlood
researchProduct

Impact of routine angiographic follow-up after angioplasty

1998

Abstract Background There is an ongoing controversy as to whether repeat coronary angiography should be routinely performed after successful percutaneous transluminal coronary angioplasty (PTCA). Methods We examined the 10-year outcome in 400 patients who had or had not undergone an angiographic control 6 months after successful PTCA and a subsequent event-free 6-month period. Our comparison was based on data gathered by questionnaire and telephone interview in 315 patients with (group A) and 85 patients without (group B) a routine 6-month angiographic control. Multivariate analysis (Cox model) was performed to identify predictors of adverse events. Results During the 10-year follow-up peri…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionUnnecessary ProceduresCoronary AngiographyDisease-Free SurvivalSurveys and QuestionnairesInternal medicineAngioplastyHumansMedicineLife Tablescardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAdverse effectAgedProportional Hazards Modelsbusiness.industryProportional hazards modelUnstable anginaMortality rateMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureBypass surgeryCardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryAmerican Heart Journal
researchProduct

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Primary HBB gene mutation severity and long-term outcomes in a global cohort of β-thalassaemia

2021

In β-thalassaemia, the severity of inherited β-globin gene mutations determines the severity of the clinical phenotype at presentation and subsequent transfusion requirements. However, data on associated long-term outcomes remain limited. We analysed data from 2109 β-thalassaemia patients with available genotypes in a global database. Genotype severity was grouped as β0 /β0 , β0 /β+ , β+ /β+ , β0 /β++ , β+ /β++ , and β++ /β++ . Patients were followed from birth until death or loss to follow-up. The median follow-up time was 34·1 years. Mortality and multiple morbidity outcomes were analyzed through five different stratification models of genotype severity groups. Interestingly, β0 and β+ mu…

AdultMalemedicine.medical_specialtyphenotypegenotypemorbidityKaplan-Meier Estimatebeta-GlobinsGene mutationβ thalassaemiaGlobal HealthGastroenterologySeverity of Illness IndexsurvivalCohort StudiesYoung AdultInternal medicineGenotypemedicineLong term outcomesOdds RatioHumansAllelesgenotype; morbidity; mortality; phenotype; survivalProportional Hazards Modelsbusiness.industrybeta-ThalassemiaDisease ManagementHematologyPrognosisPhenotypemortalityConfidence intervalPopulation SurveillanceCohortMutationFemaleRisk of deathbusinessFollow-Up Studies
researchProduct